Abstract |
The cytotoxic and genotoxic properties of the newly designed anticancer drug ' cofplaton' were investigated. Since cofplaton is a cisplatin (CDDP) plus caffeine compound, the widely applied anticancer drug CDDP alone or in combination with caffeine was studied in parallel. As measured by the MTT test the cytotoxicity of the two drugs was comparable, but cofplaton exhibited significantly fewer genotoxic side effects than CDDP in the chromosome aberration test as well as in the SCE assay. First results from animal studies indicate that cofplaton exerts antitumor activity comparable to CDDP. Because of its relatively low genotoxicity, cofplaton seems to be a promising drug in human anticancer therapy.
|
Authors | R Vogel, G Laschinski, H Spielman, W Ehrlich, B Drevenstedt, J Klosa, H Kröger |
Journal | Mutation research
(Mutat Res)
Vol. 264
Issue 4
Pg. 225-30
(Dec 1991)
ISSN: 0027-5107 [Print] Netherlands |
PMID | 1723504
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Mutagens
- Organoplatinum Compounds
- Caffeine
- Platinum
- cofplaton
- Cisplatin
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Blastocyst
- Caffeine
(analogs & derivatives, pharmacology)
- Cell Division
(drug effects)
- Cell Survival
(drug effects)
- Chromosome Aberrations
- Cisplatin
(pharmacology)
- Mice
- Mice, Inbred Strains
- Mutagens
(pharmacology)
- Organoplatinum Compounds
(pharmacology)
- Platinum
(pharmacology)
- Stem Cells
(cytology, drug effects)
|